OPEN ACCESS

Middle East Research Journal of Medical Sciences
ISSN: 2789-7699 (Print) & ISSN: 2958-2024 (Online)
Frequency: Bi-Monthly
DOI: https://doi.org/10.36348/merjms.2026.v06i02.011

KUWAIT SCHOLARS PUBLISHER
Website: http://www.kspublisher.com/
Email: office@kspublisher.com

Gene Therapy between Potentials and Challenges: Future Horizons

Dania Ali Azeiz Al-Saadi[1*], Hind Fieq Abdalameer Alhachim[1], Zainab Abdul Jabbar Al-Khafaji[2]
[1]Department of Pathological Analysis, College of Science, University of Al-Qadisiyah, Iraq
[2]College of Biotechnology, Al-Qadisiyah University

Abstract: This paper examines the latest developments in gene therapy, including its potential, challenges, and future direction. According to the article, gene therapy has the potential to help people with rare genetic diseases, boost the immune system in people suffering from cancer and infectious diseases, and offer people more options in terms of personalized medicine. However, there are technical challenges that make it difficult to apply gene therapy in real life. For example, it is not easy to insert genes into people. Additionally, there is an ethical challenge in terms of interfering with the human genome. There is also an economic challenge that might make it difficult for people to access gene therapy. However, the article indicates that gene therapy is likely to focus on the following in the future: making safe vectors, making precise gene editing using CRISPR, making use of AI in analyzing genomic data, and making sure that people get the gene therapy they need. The article ends by saying that gene therapy is a promising new direction in modern medicine, but it will only work if scientists can find a way to combine new ideas with moral and social responsibility.

Keywords: Gene Therapy, Genetic Disorders, CRISPR-Cas9, Personalized Medicine, CAR-T Cells, Ethical Challenges, Gene Editing, Future Perspectives, Molecular Medicine and Translational Research.

Review Paper

***Corresponding Author:**
Dania Ali Azeiz Al-Saadi
Department of Pathological Analysis, College of Science, University of Al-Qadisiyah, Iraq

How to cite this paper:
Dania Ali Azeiz Al-Saadi *et al* (2026). Gene Therapy between Potentials and Challenges: Future Horizons. *Middle East Res J. Med. Sci, 6*(2):160-165

Article History:
| Submit: 09.02.2026 |
| Accepted: 11.03.2026 |
| Published: 21.04.2026 |

1. INTRODUCTION

Taking into account the enormous amount of these disorders (which are in the thousands), genetic diseases constitute approximately 80% of all rare human diseases and impact around one in 17 individuals. Over the last twenty years, human genetic sequence data has accumulated rapidly and research in molecular genetics has progressed, resulting in a better understanding of the mechanisms underlying many genetic diseases. Nonetheless, standard treatments aimed at the symptoms of these conditions typically result in only a partial reduction of clinical manifestations [1]. It is important to treat these disorders and find out what is causing them. Genetic disorders can happen when the genome changes, like when DNA sequences get mutated, deleted, or added. Gene therapy is a revolutionary approach for addressing genetic disorders as it directly targets the root causes by concentrating on deleterious genetic materials, thereby yielding a durable therapeutic effect [2].

Gene therapy is one of the most important scientific discoveries in modern biomedicine. It is a new approach to treating genetic diseases by altering the genetic material in the cells. This treatment consists of introducing healthy genes into the patient's cells to cure diseases caused by genetic defects or to help the immune system and the affected cells perform better. Gene therapy techniques have greatly improved over the last few decades. For instance, gene editing techniques like CRISPR-Cas9 and viral gene editing techniques have improved things. However, there is still a lot that has to be improved. This includes ethical issues, immune system reactions, and the accuracy of gene therapy in locating the affected cells. Gene therapy has many concerns regarding costs, availability, and equity in gene therapy treatment [3].

Gene therapy is expected to play an important role in the treatment of various genetic and acquired diseases like cancer, haematological diseases, and neurological disorders, thanks to the rapid progress made in the field of biotechnology and genetic engineering. The present study aims at clarifying the scientific potential of gene therapy, the major problems that are encountered in the application of the technology, and the prospects that are offered for the future in the field of this crucial technology [4].

1.2 Potentials

1.2.1 Addressing Uncommon Hereditary Ailments

Gene therapy is a new and exciting field in the medical world that holds much promise for treating genetic diseases that cannot be cured in any other way. The basic concept behind it is to alter the genetic material in the patient's cells to correct the genetic defect that causes the disease. In some cases, the defective gene is corrected, such as in the case of cystic fibrosis or haemophilia. To correct the problem, a normal copy of this defective gene is introduced into the patient's cells. In other cases, it is an overactive gene that causes the problem. In such cases, it is possible to turn off the gene using RNAi and other techniques. This will stop the production of a bad protein. In some cases, viruses such as adenoviruses or lentiviruses are often used to deliver the normal copy of the gene into the patient's cells. These viruses are made harmless by being altered to prevent them from infecting the patient [5].

1.2.2 Individualized Medicine

Gene therapy is considered one of the most promising areas in personalised medicine, as it allows for the modification or replacement of affected genes to correspond with each patient's unique genetic profile. The main idea is that each person has a different genetic makeup, which means that treatment can be tailored to them instead of using general rules. Whole-genome sequencing or targeted sequencing are two ways to find genetic mutations. It is possible to find mutations or genetic defects that cause disease. Based on this information, a decision is made about whether gene therapy is right for the patient. Gene therapy is also used to make treatment more specific. Instead of giving all patients the same medicine, treatment is tailored to each person's genetic makeup. For example, in some blood cancers, Gene therapy can be directed at the mutation that causes the tumour to grow in the patient's body. Gene therapy in personalized medicine enables doctors to treat patients according to their individual genetic makeup. This improves the efficacy of treatment, reduces side effects, and lays the groundwork for precise medical practice [6].

1.2.3 Oncology Treatment

Gene therapy is probably the most significant new way of treating cancer at the moment. It involves altering the genetic material within the cell. It fixes genetic issues, increases the immune response, and destroys cancer cells. This technique is based on several key ideas, such as replacing tumor suppressor genes like TP53, which stop working in many types of cancer. This means putting a normal copy of the gene back into the cell so that it can control the cycle of cell division and cause cell death again. It also includes using RNA interference and CRISPR-Cas9 to stop oncogenes from working, which stops the uncontrolled growth that happens when genes like RAS and MYC mutate. Gene immunotherapy is another advanced application that involves the genetic modification of T cells to identify tumor-specific antigens, as exemplified by CAR-T technology, which has proven highly effective in treating blood cancers. Moreover, it employs the incorporation of suicide genes that render cancer cells sensitive to specific medications. The drug, once administered, morphs into a toxin that annihilates the infected cell but spares healthy cells. There have also emerged oncolytic viruses like Oncorine, which are viruses engineered at the genetic level to replicate only within cancer cells. This replication results in the cancer cells' lysis and triggers an immune response directed at them. Yet another strategy aims at inhibiting angiogenesis, a process that is essential for the nourishment of the tumor, by inactivating growth factors like VEGF. The area, though yielding encouraging outcomes, is facing serious challenges in terms of delivering genes into target cells, the possibility of unintended responses or random genome integration, differences in treatment efficacy among individuals, as well as its high cost. Nevertheless, the success of some of these applications suggests that it is going to play a central role in cancer treatment in the future, especially with advances in genetic engineering techniques [7].

1.3 Challenges

1.3.1 Technical Difficulties

Gene therapy has to be one of the most exciting new medical advances of the last few decades. Gene therapy holds promise for new ways of treating diseases that have a genetic basis or for which the cause cannot be cured. There are a lot of technical issues to be resolved for it to be practically useful. The hardest aspect of these issues is delivering therapeutic genes to target cells rapidly and accurately. This is dependent onspecialized vectors, such as altered viruses or nanoparticles, which may not always be safe and effective depending on the tissue target. This issue becomes more significant when considering the potential for inducing unwanted immune responses. If the immune system recognizes the vector or protein as foreign, the therapy may not be as effective or it may cause serious problems. Gene therapy must also consider issues such as how long the therapy will last [8]. The therapeutic effect may be ephemeral due to the potential cessation or degradation of the introduced genetic material. We need to develop technology that allows us to safely and permanently alter the genome. This shows how important it is to have technology that allows us to safely alter our genes, such as the CRISPR-Cas9 gene editing enzyme. The reason it is important to have these technologies is that it would be very dangerous to use them. This is because they have "off-target effects," which means that they could alter the genome in ways we do not plan. The reason these diseases are hard to understand is that they are very complex. The reason they are complex is that some of them, like the ones that affect only one gene, can be easily understood. The reason it would be hard to come up with a good gene therapy for these diseases is that most of them have a complex mixture of many genes. In the real world, making things and making things. This is because it would be very expensive to manufacture a lot of vectors that are safe and effective. The reason it would be expensive is that it would have to be done very precisely [9].

1.3.2 Ethical Difficulties

The debate surrounding gene therapy is not limited to scientific and technical difficulties, but also includes profound ethical challenges related to the core of medical principles and human values. Perhaps the most significant of these challenges is the distinction between treatment and enhancement. Gene therapy is considered an effective intervention when treating serious genetic diseases. But when it is thought of as a way to enhance human abilities, like cognitive or physical ones, there is a fear of "human engineering," which medicine does not need. The discussion about germline therapy gets even more heated when it comes up because treating someone on a cellular level affects not only them but also their children and grandchildren. There is a concern regarding their right to self-determination and potential unforeseen risks that may arise and remain unmanageable. The question of fair access to therapy is also brought up. Gene therapy is only available to certain groups of people because it costs a lot of money and is only available in a few medical facilities. This makes the health gap between rich and poor people, as well as between rich and poor countries, even bigger [10].

This brings up a basic question regarding how well gene therapy conforms to the equity principle in healthcare. In the field of medicine, safety and unknown risks continue to be significant issues. Genetic insertion could lead to side effects, including random mutations or severe immune reactions. Such risks make the application of the "do no harm" principle for physicians difficult, especially considering the lack of information on the long-term effects of such procedures. The matter is complicated even further when the issue of informed consent is taken into consideration, since the patient might not fully understand the implications of the scientific and technical risks involved. The question here is whether the application of the principle is effective. The possibility of the application of gene therapy for commercial, military, or the creation of so-called "designer babies" whose genetic makeup is determined based on the desires of their parents cannot be overlooked. The possibility of such practices is leading to a form of genetic discrimination and raising questions concerning what it means to be human and what we can do to change that person. Again, the ethical issues are just as complex as the technical ones, and the matter is linked to human values, justice, and the future, thus calling for the application of scientific progress in accordance with ethical requirements that ensure the progress benefits the human race without compromising its dignity and rights [11].

1.3.3 Financial Difficulties

The economic challenges associated with gene therapy have presented a major obstacle in the development and application of the technique. The first economic challenge associated with gene therapy is the high cost of the technique. The cost of making vectors using either viruses or nanoparticles, as well as conducting tests and ensuring that the vectors have met the required standards of safety, has the effect of elevating the cost of gene therapy for a single patient to hundreds of thousands of dollars and even millions of dollars. The high cost of gene therapy makes it inaccessible to a majority of patients and also poses a question about the feasibility of healthcare systems funding it. The field also faces another major challenge: the complexity of production processes. Ensuring high-quality gene vectors in adequate quantities demands a huge investment in infrastructure and technology. The investment is not only in technology and raw materials but also in adhering to strict standards set by various regulatory bodies to ensure product quality, which increases the cost of production and extends its life cycle on the market [12]. Another economic issue that arises is the limited market, considering that many gene therapies aim to cure rare diseases, which have a limited number of patients. This, therefore, makes the investment not very attractive to many pharmaceutical companies. Despite the "orphan drug" incentives, the limited returns make many companies hesitant to invest their resources in the long-term process. In addition, the issue of financing models is still emerging, considering that the current health insurance systems are not able to cover the costs of gene therapies, which, although expensive, will be used once but will have lasting effects. This, therefore, calls for the reconsideration of the current payment mechanisms, such as outcome-based payments (OBPs), which are still experimental and have not been proven to be effective. In addition, it is feared that the costs of gene therapies will make it a luxury of the wealthy nations or the financially capable, leaving the rest of the world, including the financially disadvantaged, at a loss, thereby creating a divide between the rich and the poor. It is, therefore, evident that the economic issues of gene therapies do not just relate to the cost of the therapies. It involves many issues, including the infrastructure [13].

1.4 Future Outlooks

1.4.1 Enhancing Methods for Gene Transfer

Gene delivery is an essential part of the success of gene therapy, as it provides the tools for the insertion of the therapeutic genetic material into the target cell. Although tremendous progress has been made in the delivery tools, it is still important to improve the delivery tools in order to ensure the efficacy and safety of the therapy. Traditionally, the delivery tools have been the use of viruses such as adenoviruses, adeno-associated viruses, and lentiviruses. Although they are highly effective in the delivery of the genes, they have the potential risk of causing an immune response in the host or the risk of integrating randomly in the genome of the host cell. As such, there is an ongoing effort towards the improvement of the vectors through the modification of the proteins in the viruses in order to make the delivery more precise, as well as the creation of safe viruses that have the ability to integrate in the genome only once. On the other hand, there is tremendous progress in the use of non-viral vectors, where there is ongoing research in the application of liposomes, nanoparticles, and polymeric molecules in the delivery of the genes. Although they are not [14]. But these methods need to be made better in terms of how well they work and how much damage they do to the cells they are trying to kill. Gene-editing technologies like CRISPR-Cas9 have come a long way, and it's important to keep improving gene delivery methods. This is because these technologies can only work if they can get to the right cells and make the necessary changes to the genome, either for a short time or for good. Scientists want to improve these technologies so that they can make dual-delivery systems that can deliver sgRNA and Cas9-associated proteins at the same time. The ultimate goal of these technologies is to make sure that only diseased cells get the vectors by changing them so that they only work on those cells and not on healthy ones. The method involves putting special receptors on these vectors to make them more accurate. So, improving gene delivery methods is essential to move gene therapy from the lab to the clinic. It seems that progress in this field depends on combining the development of viral and non-viral vectors, making these vectors more accurate, and using nanotechnology and protein engineering to find a balance between effectiveness and safety [15].

1.4.2 Broaden the Application of Precision Editing Technologies and CRISPR

Gene therapy's most important step forward is the emergence of the CRISPR-Cas9 gene editing tool. It is a quantum leap forward in comparison with the previously used Zinc Finger Nucleases and TALENs, in terms of the precision, speed, and cost-effectiveness of the editing of the human genome. It makes use of the guide RNA, which selects the desired nucleotide sequence, while the Cas9 enzyme cleaves the DNA at the desired site, making precise modifications in the genome, either correcting the error or inserting the desired sequence. This technology is now an essential part of many clinical trials, particularly in the treatment of single-gene disorders such as sickle cell anemia and beta-thalassemia, because of its wide use in gene therapy. However, the biggest problem that is being faced by the CRISPER technology is the issue of off-target effects, where the modifications take place in the wrong locations in the genome, leading to safety issues, after which better versions of the technology, such as the CRISPER-Cas12 and the CRISPER-Cas13, have been developed, offering better accuracy and lower error rates. Also, base editing and prime editing have become more accurate tools. Base editing lets you switch out one nitrogenous base without breaking the DNA double strand. Prime editing, on the other hand, lets you make more complicated changes, like adding or removing short nucleotide sequences in a very precise way with a very low chance of causing mutations in other places [16]. As these technologies have become better, people have made efforts to improve the delivery of these systems by using viruses like AAV, nanoparticles, and liposomes to ensure that the CRISPR system can be delivered in a safe and effective manner. These CRISPR technologies are not only limited to the treatment of rare genetic diseases. Today, people are using the technology to learn more about cancer, autoimmune diseases, and how to treat infectious diseases like HIV and SARS-CoV-2. They can be used in farming and in the environment, which has led people to have moral dilemmas about how far the technology can be taken. Thus, the use of CRISPR technology in more places is a significant step towards the new era of gene therapies. However, the success of the expansion of the use of CRISPR technologies depends upon how well we can handle the accuracy, safety, delivery, and need for rules in the application of these groundbreaking technologies [17].

1.4.3 Integrating Artificial Intelligence and Genomic Data

There has been a lot of discussion about how to use artificial intelligence (AI) and genomic data in gene therapy and precise medicine. This has generated a lot of opportunities to learn more about the human genome sequence, predict what kind of genetic disease a person will have, and find better ways to treat it. This is because a lot of data has been generated by genome sequencing and other techniques. The data has been difficult to interpret using traditional techniques because it is complex and large. This is where AI can be used to find hidden connections in the data and use them to predict a disease or a treatment outcome. An example of this would be to use a group of millions of people's genetic data to find what kind of mutations cause a disease and what kind of gene therapy, such as CRISPR, would be best used to target it. This would also include the production of certain drugs. AI can be used to produce modified proteins of the Cas type that can be used for vectors [18]. This information can be combined with other sets of information, like electronic medical records or environmental information, in order to have the complete picture. This is in line with the notion of personalized medicine, which argues that each and every patient should be given the right kind of treatment according to his or her own genetic makeup. However, this makes things more complicated, especially with the issue of safety and privacy. It is very imperative that the right measures are taken when dealing with this kind of sensitive information in order to ensure that businesses and people are not using this information for their own gain. Additionally, the over-reliance of algorithms may bring ethical concerns since the whole process is not clear. Thus, the use of artificial intelligence and genomic information is a new trend that will help the practice of gene therapy transition from the research level to the clinical level faster. However, the trend will only be effective if it can find a balance between morality and technology [19].

1.4.4 Equitable Access

Fair access to gene therapy is one of the most important topics in current talks about health and ethics. Gene therapy has amazing potential for treating genetic and incurable diseases, but there is a big problem with health equity because there is a big gap between its scientific promise and its availability to patients. One of the problems with this issue is that it cos a lot of money. Gene therapy can cost hundreds of thousands or even millions of dollars per person. This means that only a small number of people, who are wealthy and/or have insurance, may be able to afford it. People in low- and middle-income countries may not be able to afford it at all.=. This could make gene therapy an elitist technology that makes health differences between rich and poor people even worse. It's also important to note that gene therapy research centers and clinics are mostly located in a small number of developed countries. This means that a lot of people in the world can't get these treatments, even if they have the money to pay for them. This is also related to how weak the medical infrastructure is in some countries, which makes it even harder to use these technologies. In addition to costs and location, the issue of openness in clinical trials is another problem. Patients' backgrounds might not allow them to participate in the tests, making it even harder for people to receive these treatments at an early stage. Some ideas that can help solve these problems include coming up with new ways of paying for things, like outcome-based payment plans or long-term premiums, and investing in gene therapy at large, such that we do not rely on companies to do it [20]. It is also important to foster international cooperation in the fields of research, production, and exchange of these technologies, in such a way that the equitable distribution of these treatments in the world is ensured. Thus, the equitable access of gene therapy transcends the economic or medical dimension, reaching the ethical or social dimension that is associated with the human right to health. Thus, the future of gene therapy will not only depend on the scientific progress that is achieved, but also on the potential that it has as an instrument of health justice without contributing to inequality [21].

CONCLUSION

Thus, from the analysis of the prospects and challenges of gene therapy, it can be concluded that gene therapy is on the verge of entering a revolutionary stage in the history of medicine. It has the potential to change the way we treat genetic, chronic, and incurable diseases. This has given hope to millions of patients worldwide. However, the problems that are associated with gene therapy are such that we have to be careful and informed enough to appreciate its potential as a therapy for diseases, as well as its safe and effective application in the context of human values and health equity. Looking forward to the future of gene therapy, it seems that gene therapy has the potential to become an integral part of medicine in the twenty-first century due to the advancements that are being made in the field of gene editing, the application of artificial intelligence in the analysis of genomic information, and the efforts that are being made to ensure that gene therapy becomes accessible to the people of the world. Thus, it can be asserted that the future of gene therapy depends on the extent to which equilibrium can be achieved between aspiration and accountability.

REFERENCES

1. Jackson, M., Marks, L., & Wilson, J. B. (2018). The genetic basis of disease. Essays in Biochemistry, 62(4), 413–423.
2. Bhatia, S., Le Cam, Y., Carrion, J., Diamond, L., Fennessy, P., Gassman, S., Gutzwiller, F., Kagan, S., Pankevich, D., Young Maloney, J., Mahadev, N., Schulz, M., Wong-Rieger, D., & Morgese, P. (2024). Strengthening health systems for access to gene therapy in rare genetic disorders. Molecular Therapy – Methods & Clinical Development, 32, 101220.
3. Gonçalves, G. A. R. (2017). Gene therapy: Advances, challenges and perspectives. Gene Therapy, 24(11), 723–732.
4. Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023). Successes and challenges in clinical gene therapy. Gene Therapy, 30(10–11), 738–746.
5. Geng, G., Zhang, Y., & Wang, J. (2025). Viral and non-viral vectors in gene therapy: Current state and future perspectives. Advanced Drug Delivery Reviews, 180, 114–131.

6. Singh, D. (2024). Personalized medicine: An alternative for cancer treatment. Journal of Personalized Medicine, 14(4), 123–135.
7. Watanabe, N. (2020). Clinical CAR-T cell and oncolytic virotherapy for cancer. Frontiers in Immunology, 11, 1855.
8. Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR gene therapy: Applications, limitations, and implications for the future. Frontiers in Oncology, 10, 1387.
9. Park, S.J. (2025). Recent applications, future perspectives, and limitations of CRISPR-Cas gene editing. Molecular Therapy - Nucleic Acids, 27, 1-14.
10. Macpherson, I. (2019). Ethical challenges of germline genetic enhancement. Frontiers in Genetics, 10, 767.
11. Joseph, A. M. (2022). Ethical perspectives of therapeutic human genome editing. Frontiers in Genetics, 13, 979343.
12. Phares, S. (2024). Managing the challenges of paying for gene therapy. Institute for Clinical and Economic Review.
13. Phares, S., Trusheim, M., Emond, S. K., & Pearson, S. D. (2024). Managing the challenges of paying for gene therapy: Strategies for market action and policy reform. Institute for Clinical and Economic Review (ICER) and NEWDIGS at Tufts Medical Center.
14. Li, L. (2018). Non-viral delivery systems for CRISPR/Cas9-based genome editing. Journal of Controlled Release, 271, 1–18.
15. Xu, C. L. (2019). Viral delivery systems for CRISPR. Frontiers in Bioengineering and Biotechnology, 7, 1.
16. Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018). Delivering CRISPR: A review of the challenges and strategies. Molecular Therapy – Methods & Clinical Development, 10, 1–10.
17. Xu, Y., Zhang, Y., & Liu, H. (2020). CRISPR-Cas systems: Overview, innovations, and applications. Frontiers in Microbiology, 11, 1.
18. O'Connor, O., & McVeigh, T. P. (2025). Increasing use of artificial intelligence in genomic medicine for cancer care: The promise and potential pitfalls. BJC Reports, 3(20).
19. Quazi, S. (2022). Artificial intelligence and machine learning in precision medicine. Journal of Clinical Medicine, 11(15), 4523.
20. Cornetta, K. (2018). Equitable access to gene therapy: A call to action for the global community. Human Gene Therapy, 29(11), 1165–1171.
21. Cornetta K., Bonamino M., Mahlangu J., Mingozzi F., Rangarajan S., Rao J. (2022). Gene therapy access: global challenges, opportunities, and views from Brazil, South Africa, and India. Mol. Ther. 30 (6), 2122–2129.